Evelo Biosciences (EVLO) Competitors $0.0005 0.00 (0.00%) As of 07/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsShort InterestTrendsBuy This Stock EVLO vs. SCPS, VAXX, NAVB, CMRA, GNCAQ, GNCA, ARDS, STAB, AMPE, and EFTRShould you be buying Evelo Biosciences stock or one of its competitors? The main competitors of Evelo Biosciences include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Navidea Biopharmaceuticals (NAVB), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Evelo Biosciences vs. Its Competitors Scopus BioPharma Vaxxinity Navidea Biopharmaceuticals Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Ampio Pharmaceuticals eFFECTOR Therapeutics Evelo Biosciences (NASDAQ:EVLO) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation. Which has preferable valuation and earnings, EVLO or SCPS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvelo BiosciencesN/AN/A-$114.53MN/AN/AScopus BioPharmaN/AN/A-$11.61MN/AN/A Is EVLO or SCPS more profitable? Company Net Margins Return on Equity Return on Assets Evelo BiosciencesN/A N/A N/A Scopus BioPharma N/A N/A N/A Do insiders & institutionals have more ownership in EVLO or SCPS? 0.3% of Evelo Biosciences shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the media prefer EVLO or SCPS? In the previous week, Evelo Biosciences had 2 more articles in the media than Scopus BioPharma. MarketBeat recorded 2 mentions for Evelo Biosciences and 0 mentions for Scopus BioPharma. Evelo Biosciences' average media sentiment score of 0.32 beat Scopus BioPharma's score of 0.00 indicating that Evelo Biosciences is being referred to more favorably in the media. Company Overall Sentiment Evelo Biosciences Neutral Scopus BioPharma Neutral Which has more risk & volatility, EVLO or SCPS? Evelo Biosciences has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Scopus BioPharma has a beta of -0.19, indicating that its stock price is 119% less volatile than the S&P 500. SummaryEvelo Biosciences beats Scopus BioPharma on 4 of the 6 factors compared between the two stocks. Get Evelo Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVLO vs. The Competition Export to ExcelMetricEvelo BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9K$772.21M$5.71B$9.51BDividend YieldN/A4.84%4.60%3.99%P/E RatioN/A1.3928.0720.02Price / SalesN/A26.96459.47103.02Price / CashN/A19.5636.5558.97Price / BookN/A6.798.615.88Net Income-$114.53M-$4.32M$3.24B$258.50M7 Day PerformanceN/A1.31%3.83%2.03%1 Month PerformanceN/A3.68%10.40%12.52%1 Year PerformanceN/A8.08%34.13%19.07% Evelo Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVLOEvelo BiosciencesN/A$0.00flatN/AN/A$9KN/A0.00120News CoverageOptions VolumeSCPSScopus BioPharmaN/A$0.00flatN/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-56.0%$13KN/A0.0090Gap UpNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-50.0%$10K$8.13K0.0010CMRAComera Life SciencesN/A$0.00flatN/AN/A$6K$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00+∞N/AN/A$5KN/A0.0030Gap UpSTABStatera BiopharmaN/A$0.00flatN/A-83.3%$5KN/A0.0020Negative NewsHigh Trading VolumeAMPEAmpio PharmaceuticalsN/A$0.00-73.0%N/A+145.5%$3KN/A0.0020Gap DownEFTReFFECTOR Therapeutics0.073 of 5 stars$0.00flatN/A-99.6%$1KN/A0.0010Upcoming Earnings Related Companies and Tools Related Companies SCPS Alternatives VAXX Alternatives NAVB Alternatives CMRA Alternatives GNCAQ Alternatives GNCA Alternatives ARDS Alternatives STAB Alternatives AMPE Alternatives EFTR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVLO) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evelo Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVLO Stock Alerts